1-6 of 6
Nan Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials

Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, Dongsheng Tu, Stephanie Y. Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O'Callaghan, Jonathan M. Loree
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1121–1130.
https://doi.org/10.1158/1078-0432.CCR-23-3275
Published: 15 March 2024
View article titled, Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Open the PDF for Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis

Hsiang-Fong Kao, Bin-Chi Liao, Yen-Lin Huang, Huai-Cheng Huang, Chun-Nan Chen, Tseng-Cheng Chen, Yuan-Jing Hong, Ching-Yi Chan, Jean-San Chia, Ruey-Long Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1560–1571.
https://doi.org/10.1158/1078-0432.CCR-21-3025
Published: 14 April 2022
View article titled, Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
Open the PDF for Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis in another window
Journal Articles

Abstract A29: The CUTO panel of patient-derived NSCLC cell lines reveals unique molecular characteristics and responses to targeted therapies

Anh Tuan Le, Adriana Estrada-Bernal, Laura Schubert, Andrea Doak, Nan Chen, Kurtis Davies, Aria Vaishnavi, Mary Jackson, Vignesh Narayana, Kimi Kondo, John Mitchell, Michael Weyant, Tom Purcell, Paul Bunn, Ross Camidge, Janet Freeman-Daly, Robert Doebele
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): A29.
https://doi.org/10.1158/1557-3265.AACRIASLC18-A29
Published: 01 September 2018
View article titled, Abstract A29: The CUTO panel of patient-derived NSCLC cell lines reveals unique molecular characteristics and responses to targeted therapies
Journal Articles

Abstract B53: Cytotoxic effect of 21kDa protein and antitumor effect of 31KDa protein derived from mushroom, schizophyllum commune

Yu-Sheng Wu, Po-Yen Chang, Su-Nan Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): B53.
https://doi.org/10.1158/1078-0432.TCMUSA10-B53
Published: 02 February 2016
View article titled, Abstract B53: Cytotoxic effect of 21kDa protein and antitumor effect of 31KDa protein derived from mushroom, schizophyllum commune
Journal Articles

HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s

Ling Li, Wenhua Tang, Xiaoqing Wu, David Karnak, Xiaojie Meng, Rachel Thompson, Xinbao Hao, Yongmin Li, Xiaotan T. Qiao, Jiayuh Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, Liang Xu
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6703–6715.
https://doi.org/10.1158/1078-0432.CCR-13-0621
Published: 16 December 2013
View article titled, HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Open the PDF for HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s in another window
Includes: Supplementary data
Journal Articles

Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization

J. Jack Lee, Nan Chen, Guosheng Yin
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4498–4507.
https://doi.org/10.1158/1078-0432.CCR-11-2555
Published: 30 August 2012
View article titled, Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization
Open the PDF for Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization in another window
Includes: Supplementary data